Previous close | 1.1000 |
Open | 1.1000 |
Bid | 1.7000 |
Ask | 1.9000 |
Strike | 24.00 |
Expiry date | 2024-08-16 |
Day's range | 1.1000 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | 42 |
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.